Transpek Industry Ltd Q2 FY26 – Chlorine ke Badshah, Margin ke Maharaja, aur Customs ke Casualties!
1. At a Glance
Transpek Industry Ltd (TIL), the Vadodara-based chemical veteran from the Excel Group, continues to mix chlorine and comedy in its Q2 FY26 performance. At a CMP of ₹1,342, the company’s market cap stands at ₹750 crore — basically the value of a good mid-sized FMCG brand’s advertising budget. But unlike FMCG, Transpek sells fumes and acids, not feelings. The company trades at a humble P/E of 12.9 — cheaper than your Netflix subscription per molecule — and an EV/EBITDA of just 5.07, hinting that the market still doesn’t fully “get” this chlorination champion.
The latest quarterly sales came in at ₹160 crore, slightly down 1.5% QoQ (probably because half the world’s customs officers were inspecting their shipments), but profits jumped 32% QoQ to ₹12.6 crore. That’s called margin magic — or maybe “sulphuric surprise.” Over 88% of revenue still comes from exports, proving once again that India’s air, soil, and sometimes export invoices are global. ROE at 7.75% and ROCE at 10% look decent, but the real flex is their balance sheet — near zero debt (₹40.8 crore), healthy dividend yield of 1.49%, and a book value per share of ₹1,375.
In short: They’re like that 60-year-old chemist uncle who doesn’t talk much but quietly makes millions exporting acid chlorides to Europe.
2. Introduction
If chemistry had rockstars, Transpek would be the Kishore Kumar of chlorination — seasoned, classic, and slightly underrated. Incorporated in 1965 (when black-and-white Doordarshan was still new), this Excel Group company learned early that India doesn’t just need sugar, steel, and soap — it needs sulphur dichloride.
From the outside, the company seems boring: it makes chemicals. But dive deeper and you find a firm that supplies to pharma giants, agrochemical leaders, and pigment producers across the globe — from the USA to Japan. Their products end up in medicines, dyes, detergents, and even the air you breathe (hopefully filtered).
Despite all the global footprints, Transpek has remained a family affair — and like every family business, it’s had its share of drama. Between expanding to 66,000 MTPA production capacity and handling customs penalties of ₹12 crore (oops), the company’s story reads like a Bollywood thriller — “Chemical Dilwale Export Le Jayenge.”
And what’s more, they just withdrew their NSE listing proposal because their paid-up capital didn’t meet the ₹10 crore threshold. Basically, they said, “NSE, hum gareeb log hain, BSE hi sahi hai.”
3. Business Model – WTF Do They Even Do?
Transpek doesn’t sell products; it sells reactions. Literally.
Its expertise lies in mastering dangerous, high-temperature chemical reactions like chlorination, sulfonation, Friedel-Crafts, and amidation — all words that make chemistry students cry. But for TIL, they’re cash cows. Their Ekalbara, Vadodara plant — spread across 100 acres — manufactures a vast portfolio of acid chlorides, alkyl chlorides, and intermediates that feed into sectors like:
Pharma: Making molecules that make medicines.
Agrochemicals: Stuff that kills pests but hopefully not profits.
Polymers and Dyes: Because fashion and fertilizers both need chemistry.
Surfactants: Fancy name for soap chemicals that keep you clean while the planet gets dirty.
The company’s top products — Thionyl Chloride, Sulphur Dichloride, and a host of acid chlorides — are shipped to 20+ countries including the USA, Germany, Japan, and South Korea.
About 65% of its revenue comes from the Polymer segment, 14% from Specialty, 11% from Pharma, and the rest from Others. And here’s the fun bit — 88% of total sales are exports. Basically, they’re more global than some Indian IT companies.
Their biggest challenge? Customer concentration. The top 6 customers contribute ~78% of revenues. So if one client sneezes, Transpek catches a chlorine cold.
4. Financials Overview
Quarterly Comparison Table (₹ crore)
Metric
Sep 2025
Sep 2024
Jun 2025
YoY %
QoQ %
Revenue
160
163
154
-1.8%
3.9%
EBITDA
27
23
24
17.4%
12.5%
PAT
13
10
16
30.0%
-18.7%
EPS (₹)
22.63
17.10
27.89
32.4%
-18.9%
Annualised EPS = ₹22.63 × 4 = ₹90.52 P/E = 1342 / 90.52 = 14.8x (slightly above screener’s trailing value due to rounding).
Commentary: Revenue stayed flat, but profits bounced like a well-timed chemical reaction. Margins expanded as operating efficiency improved — or maybe chlorine got cheaper. Either way, the
